TETRA BIO-PHARMA INC Stock News

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced Thursday that the company received a notice of compliance for its Drug Establishment License (DEL) following an audit by the Drug GMP

Tetra Bio-Pharma Inc. receives a Notice of Compliant rated inspection to distribute pharmaceuticals Key milestone in the development path to commercialization of Reduvo OTTAWA, ON / ACCESSWIRE / April

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced Tuesday that it has received positive feedback from Health Canada on its application for a clinical trial on ARDS-003 for coronavirus

Health Canada acknowledges that the preclinical safety data are robust and sufficient to file a Clinical Trial Application aimed at treating hospitalized COVID-19 patients at risk of developing ARDS A

Tetra Bio-Pharma Inc (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1) said on Friday that the biotechnology company has initiated other research projects with Targeted Pharmaceuticals, through its research agreement

Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program The addressable glo

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) has announced that its contract manufacturing facility, Quantum Pharma Inc., has received a notice of compliance for its Drug Establishment Li

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) has announced that its contract manufacturing facility, Quantum Pharma Inc., has received a notice of compliance for its Drug Establishment Li

Quantum Pharma Inc. is a contract facility operated by Tetra Bio-Pharma Inc Quantum Pharma Inc. receives a Notice of Compliant rated inspection OTTAWA, ON / ACCESSWIRE / March 18, 2021 / Tetra Bio-Pha

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced that the company's Dronabinol Soft Gel capsules have completed the screening phase of the New Drug Submission (NDS) file submitted to

Reduvo™ would be Canada's only DIN for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / March 15, 2021 / Tetra Bio-Pharma Inc. ("Tet

OTTAWA, ON / ACCESSWIRE / March 8, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development wish

OTTAWA, ON / ACCESSWIRE / March 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announ

Tetra Bio-Pharma Inc. (TSX:TBP) said it has closed its previously announced bought-deal public offering of units or aggregate gross proceeds to the company of $14,421,000. The company said a total o

Tetra Bio-Pharma Inc (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) said it has signed a letter of intent (LOI) with Danish company DanCann Pharma for the exclusive distribution of its Reduvo Adversa and QIXLEEF